

Clinical Trial Protocol

Iranian Registry of Clinical Trials

25 Sep 2026

Evaluation of Efficacy of BBSB type C in comparison with needle subcision on atrophic acne scar

Protocol summary

Study aim

Determine the efficacy and safety of subcision with barikbins-blunt-subcision-blade type C in comparison with Needle No. 22 in the treatment of atrophic acne scars

Design

In this study, 32 patients with atrophic acne scars in both sides of their face referred to Shahdai Hospital during the period of 1395 to 1396 were evaluated for inclusion criteria and exclusion criteria. The two sides of the face are randomly divided into two groups A and B, and analysts and patients are not aware of the type of group and only the surgeon is aware of the study group.

Settings and conduct

This randomized clinical trial was conducted in patients with atrophic acne scars in two parts of their face who referred to laser clinic of Shohadaye Tajrish Hospital. The two sides of the patients were randomly divided into two groups, and analysts and patients are unaware of the type of group and only the surgeon is aware of the study group.

Participants/Inclusion and exclusion criteria

Inclusion criteria : age 18 to 50 years; complete patient satisfaction; participation in atrophic acne scars on both sides of the species with relatively similar severity on both sides; Exclusion criteria: active nodulosistic acne (more than 6 papules or nodule on each side of the face); active skin infection (for example, herpes simplex or jaundice infection); hematological disorders or coagulopathy; Immunosuppression; dermatological diseases interact with the procedure; previous history of colloid; use of medications that prolong the bleeding time (especially aspirin, warfarin or vitamin E); isotretinoin in the last 12 months; resurfacing in 6 Last month included dermabrasion, laser therapy, chemical peeling; pregnancy or breastfeeding;

Intervention groups

Face A side: Under subcision with BBSB type C. Face B side: Perform subcision with the needle number 22.

Main outcome variables

Severity of atrophic scars

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20111121008146N29**

Registration date: **2018-01-21, 1396/11/01**

Registration timing: **retrospective**

Last update: **2018-01-21, 1396/11/01**

Update count: **0**

Registration date

2018-01-21, 1396/11/01

Registrant information

Name

Mohammadreza Razaghi

Name of organization / entity

Laser application in medical sciences research center

Country

Iran (Islamic Republic of)

Phone

+98 21 2271 8021

Email address

laser.cntr@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2017-02-19, 1395/12/01

Expected recruitment end date

2018-02-20, 1396/12/01

Actual recruitment start date

2015-03-21, 1394/01/01

Actual recruitment end date

2016-03-20, 1395/01/01

Trial completion date
empty

Scientific title
Evaluation of Efficacy of BBSB type C in comparison with needle subcision on atrophic acne scar

Public title
The effect of subcision on acne scar

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
 Age 18 to 50 years old Patient's complete consent to participate in the study Acne atrophic scars on both sides of the species with a relatively uniform intensity on both sides
Exclusion criteria:
 Active nodulosistic acne (more than 6 papules or nodules on each side of the face) Active skin infection (herpes simplex or jaundice infection) Hematological disorders or coagulopathy Immunosuppression Dermatological diseases interfere with the procedure Previous biography of colloids Taking medications that prolong the bleeding time (especially aspirin, warfarin or vitamin E) Isotretinoin intake over the past 12 months Performing resurfacing procedures over the past 6 months include dermabrasion, laser therapy, chemical peeling Pregnancy or breastfeeding

Age
From **18 years** old to **50 years** old

Gender
Both

Phase
N/A

Groups that have been masked

- Participant
- Data analyser

Sample size
 Target sample size: **32**
 More than 1 sample in each individual
 Number of samples in each individual: **2**
 One side of the face treated with subcision and the other side treated with needle.
 Actual sample size reached: **32**
 More than 1 sample in each individual
 Actual sample size in each individual: **2**
 One side of the face treated with subcision and the other side treated with needle.

Randomization (investigator's opinion)
Randomized

Randomization description
The patient's face are divided into two intervention groups 1 and 2 according to a simple randomized 1: 1 random number table. The analyst and the patient are not aware of the groups.

Blinding (investigator's opinion)
Double blinded

Blinding description
The group and side of the face are placed in pairs and in

dark envelopes. It is available to the surgeon and only the surgeon is informed of the patient's healing side. Procedures in this project are done by a skilled dermatologist. The envelope will be opened by a physician only after initial evaluations in each person, and neither patients nor analysts will be aware of the groups.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
 Ethics committee of Shahid Beheshti University of Medical Sciences
Street address
 Next to Ayatollah Taleghani Hospital, Shahid Arabi ST. Yemen street, Shahid Chamran highway, Tehran
City
 Tehran
Province
 Tehran
Postal code
 1989934148

Approval date
2017-02-05, 1395/11/17

Ethics committee reference number
IR.SBMU.RETECH.REC.1395.927

Health conditions studied

1

Description of health condition studied
Atrophic acne scar

ICD-10 code
L99

ICD-10 code description
Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Primary outcomes

1

Description
Severity of atrophic scars

Timepoint
Before starting treatment, in the first week after treatment, the first month, the third month and the sixth month after treatment

Method of measurement

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group1: The A side is required to be subcision to BBSB type C. The site of the entry of the subcision blade is at a point in the 1 cm front and 2 cm ahead of the ear tragus. Iodine is used to sterilize the area. Tomsent solution is combined with 50 cc of lidocaine, 1% pure, 1 cc epinephrine, 0.1% and 10 cc of sodium bicarbonate solution, 4.2% in normal saline 1 liter for local anesthetic. 50 to 100 cc of this solution is injected in a sub-dermal plaque with gauge 23 needle at 4 to 7 dots. For subcision, BBSB type C is used. Through the inlet area that has already been identified and numb, the blade number C is entered on the parallel plan with the skin on the subdermal plate and the smooth surface of the blade is facing up (the index of the thumb is on the handle to indicate it) All fibrous bands are released by moving forward and backward, and by moving the pseudo-fan, the blade is moved to the adjacent portions. The blade is moved slowly to avoid excessive force and damage to the nerves and vessels and to the skin. Also, the lack of movement of the blade to the lateral will also help prevent this damage. About two-thirds of the length of the blade can be entered into the skin and used from an entrance area for the entire scar area of the face side. After the procedure, an antibiotic with an without pressure gas for simple dressing is used. Oral antibiotics or anti-viral antibiotics are prescribed according to individual needs. Patients are educated about the possibility of edema, bruising, mild thrombosis in the first few days. Patients are advised to sleep semi sitting for two nights to reduce swelling.

Category

Treatment - Devices

2

Description

Intervention group2: On the B side, perform the subcision with the needle number 22. After determining the range and location of atrophic scars with non-toxic surgical markers, the range is averaged by about 10 cc of lidocaine-2% pure without epinephrine. For subcision, 22-gauge needles are used for deep-scarves and 27-gauge scarves for surface scars attached to a 1-cc syringe. The skin of the patient is pinched or stretched by a non surreptitious surgeon to make the skin firm and non-moving. By inserting the needle from the proximal axial atrophic scar, the fibrous bands are released by forward movement and lateral movement in parallel planes of the skin and in the scars area and about 1 mm from the margin. For each atrophic scar, at least one entry point and sometimes a needle insertion area are required. The ultimate goal is to move the needle from

the horizontal to the lateral, along with a mild hematoma in the atrophic scar region and a swelling in the surface of the scar. Hemostasis is done by placing a non-pressure gas in the area. The maximum number of atrophic scars in the patient's range will be treated on that side. After the procedure, an antibiotic with an without pressure gas for simple dressing is used. Oral antibiotics or anti-viral antibiotics are prescribed according to individual needs. Patients are educated about the possibility of edema, bruising, mild thrombosis in the first few days. Patients are advised to sleep semi sitting for two nights to reduce swelling.

Category

Treatment - Devices

Recruitment centers

1

Recruitment center

Name of recruitment center

Shohadaye Tajrish Hospital

Full name of responsible person

Dr Behrouz Barikbin

Street address

Shohadaye Tajrish Hospital, Tajrish, Tehran

City

Tehran

Province

Tehran

Postal code

1989934148

Phone

+98 21 2274 9221

Email

laser.cntr@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dr Afshin Zarghi

Street address

Next to Ayatollah Taleghani Hospital, Shahid Arabi ST.
Yemen street, Shahid Chamran highway, Tehran

City

Tehran

Province

Tehran

Postal code

1989934148

Phone

+98 21 2274 9221

Email

laser.cntr@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor

organization/entity?

Yes

Title of funding source

Shahid beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dr Behrouz Barikbin

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Shohadaye Tajrish Hospital, Tajrish, Tehran

City

Tehran

Province

Tehran

Postal code

1989934148

Phone

+98 21 2274 9221

Email

laser.cntr@yahoo.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dr Behrouz Barikbin

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Shohadaye Tajrish Hospital, Tajrish, Tehran

City

Tehran

Province

Tehran

Postal code

1989934148

Phone

+98 21 2274 9221

Email

laser.cntr@yahoo.com

Person responsible for updating data**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Dr Behrouz Barikbin

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Shohadaye Tajrish Hospital, Tajrish, Tehran

City

Tehran

Province

Tehran

Postal code

1989934148

Phone

+98 21 2274 9221

Email

laser.cntr@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available